Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2020

View Archived Issues

Researchers achieve the reversal of HIV and SIV latency in vivo

Chromosome amplification drives cancer progression via effects on secretion

Fat or fiber, cFAP activation is problematic for heart

Novel panaxatriol derivative shows efficacy in rat model of MI/R injury

Phase Ia/b data presented for PL-MLP in patients with metastatic CRC

ALPN-101 demonstrates efficacy in preclinical models of chronic IBD

FDA issues clinical hold on the phase III POLAR program of PledOx

Colorectal cancer among those affected by periostin

CEPI awards funding to support development of vaccines against coronavirus 2019-nCoV

Jiangsu Hengrui Medicine, Shanghai Hengrui patent TLR8 agonists

Incyte describes new adenosine A2A and/or A2B receptor antagonists

PIKfyve inhibitors identified at MFMER, Sanford Burnham Prebys Medical Discovery Institute

Protein cereblon inhibitors discovered at Kymera Therapeutics

The University of Minnesota presents psi-glutathione compounds

PDE3A influences endothelial function and risk of ischemic stroke

Phase III study of AKP-01 spray in mild to moderate plaque psoriasis meets primary endpoint

Pivotal DESTINY-Gastric01 trial of DS-8201 meets primary endpoint

CStone begins phase III study of CS-1003 in advanced hepatocellular carcinoma

Dynacure studies DYN-101 in phase I/II trial for centronuclear myopathies

Brilinta improves outcomes after acute ischemic stroke or TIA in phase III trial

Phase I results with EPX-100 pave way for phase II studies in Dravet syndrome

Phase III BREEZE-AD4 trial of baricitinib in atopic dermatitis meets primary endpoint

Daiichi Sankyo begins phase I study in Japan with DS-2741a for atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...